Phase 3 N=46 Confocal Endomicroscopy for Barrett's Esophagus
Barrett's Esophagus · Esophageal Adenocarcinoma
Primary: Diagnostic Yield for Neoplasia in High Risk Patients(Suspected Neoplasia) — 34; 17 percent yield for neoplasia — p=0.01
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 3 N=2,186 Study Evaluating The Safety And Efficacy Of Desvenlafaxine Succinate For Vasomotor Symptoms In Menopausal Women
Vasomotor Symptoms
Primary: Change From Baseline in the Average Daily Number of Moderate to Severe Hot Flushes at Week 4 — -6.52; -3.64 Hot Flushes — p=<0.001
Phase 3 N=49 Long Term Safety of Clopidogrel in Neonates/Infants With Systemic to Pulmonary Artery Shunt Palliation
Heart Defects, Congenital
Primary: Number of Participants With Bleeding Events — 0; 2; 0; 0 participants
Phase 3 N=129 Safety and Tolerability Study Comparing Sodium Oxybate Given as an Oral Solution to a Single-blinded Combination of Oral Tablets Plus Oral Solution in Subjects With Fibromyalgia
Fibromyalgia
Primary: Summary of Most Frequent Adverse Events (Per Arm) Experienced by Study Subjects — 20; 21; 21; 23 participants
Phase 3 N=64 A Study for Evaluating the Efficacy and Safety of Zonisamide and Lamotrigine (Lamictal) for Subjects With Refractory Simple Partial, Complex Partial or Partial With Secondary Generalized Seizures
Epilepsy
Primary: The Percentage Change of Monthly Seizure Frequency at the End of the 16-week Treatment From Baseline — -32.7; -35.6 percent change — p=0.240
Phase 3 N=91 Short Term Relief of Eustachian Tube Dysfunction and Serous Otitis Media Using Intranasal Steroid Sprays
Otitis Media, Serous · Negative Middle Ear Pressure · Rhinitis
Primary: Number of Subjects With Complete Normalization of Abnormal Tympanometry, Regardless of Additional Treatment — 7; 12 participants — p=0.18
Phase 3 N=515 A Study to Test the Effect of MK0217A on Vitamin D Inadequacy in Postmenopausal Women With Osteoporosis (0217A-262)
Osteoporosis
Primary: Percentage of Participants With Serum Levels of 25-hydroxyvitamin D Below 20 ng/mL at Week 26 — 8.6; 31.0 Percentage of Participants — p=<0.001
Phase 3 N=44 Viral Kinetics Study of Telbivudine and Entecavir in Adults With Chronic Hepatitis B
Hepatitis B · Chronic Hepatitis B
Primary: Change in Mean Hepatitis B Virus (HBV) DNA Levels — 10.290; 9.721; 3.669; 3.194 log10 copies/mL
Phase 3 N=326 Clobetasol Propionate 0.05% Shampoo in Association With Antifungal Shampoo in Scalp Seborrheic Dermatitis
Scalp Seborrheic Dermatitis
Primary: Total Severity Score (TSS): Percent Change From Baseline at Week 4 — -71.4; -66.7; -66.7; -57.1 Percent change — p=<0.01
Phase 3 N=1,800 A Study to Evaluate the Immunogenicity of Quadrivalent LAIV in Adults 18 to 49 Years of Age
Healthy or Stable Underlying Chronic Medical Condition
Primary: The 4 Post-dose Strain-specific Serum Hemagglutination Inhibition (HAI) Antibody Geometric Mean Titers (GMT) in the Q/LAIV (MEDI3250) Arm Are Noninferior to Those in the…
Phase 3 N=30 Trial to Compare the Efficacy of Systane Ultra and Refresh Drop in the Treatment of Dry Eye in Asian Eyes
Xerophthalmia · Blepharitis
Primary: Visual Analog Score (VAS) — 21.55; 27.27 scores on a scale — p=>0.05
Phase 3 N=390 Efficacy and Safety Study of Alogliptin and Insulin in the Treatment of Type 2 Diabetes.
Diabetes Mellitus
Primary: Change From Baseline in Glycosylated Hemoglobin (HbA1c) at Week 26. — -0.13; -0.63; -0.71 percentage of Glycosylated Hemoglobin — p=<0.001
Phase 3 N=240 Trial Comparing Atropine to Atropine Plus a Plano Lens for the Sound Eye for Amblyopia in Children 3 to <7 Years Old
Amblyopia
Primary: Visual Acuity Mean Score in the Amblyopic Eye — 0.23; 0.22; 0.54; 0.50 logMAR units — p=0.21
Phase 3 N=335 Fludarabine (Fludara®) Plus Alemtuzumab (CAMPATH®, MabCampath®) vs Fludarabine Alone in B-Cell Chronic Lymphocytic Leukemia (B-CLL) Patients
B-Cell Chronic Lymphocytic Leukemia
Primary: Kaplan-Meier Estimates for Progression-free Survival (PFS) Based on Independent Response Review Panel (IRRP) Assessment — 23.65; 16.48 months — p=<0.001
Phase 3 N=240 Efficacy and Safety Study on Menatetrenone in the Treatment of Postmenopausal Osteoporosis Women
Postmenopausal Osteoporosis
Primary: Bone Mineral Density BMD (Percentage) Change in Lumber Spine After 12 Months — 1.22; 2.17 percentage of BMD — p=0.26